The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis

Molecular and Cellular Endocrinology

Volumn 380, Issue 1-2, 2013, Pages 99-107

  Fischer, Henrike J ^a   Schweingruber, Nils ^a   Lühder, Fred ^a   Reichardt, Holger M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Chemokines; Glucocorticoids; Migration; Neuroinflammation; T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CYTOCHALASIN D; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FREUND ADJUVANT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; LATRUNCULIN A; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MINERALOCORTICOID RECEPTOR; MITOXANTRONE; NATALIZUMAB; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL STRUCTURE; CHEMOTAXIS; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; HISTORY OF MEDICINE; HUMAN; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; POLARIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

CHEMOKINES; GLUCOCORTICOIDS; MIGRATION; NEUROINFLAMMATION; T CELLS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL ADHESION MOLECULES; CHEMOTAXIS, LEUKOCYTE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLUCOCORTICOIDS; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 84884531608     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.04.001     Document Type: Article

References (122)

1. Allenspach E.J., Cullinan P., Tong J., Tang Q., Tesciuba A.G., Cannon J.L., Takahashi S.M., Morgan R., Burkhardt J.K., Sperling A.I. ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. Immunity 2001, 15:739-750.
2. Ara T., Itoi M., Kawabata K., Egawa T., Tokoyoda K., Sugiyama T., Fujii N., Amagai T., Nagasawa T. A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo. J. Immunol. 2003, 170:4649-4655.
3. Barten L.J., Allington D.R., Procacci K.A., Rivey M.P. New approaches in the management of multiple sclerosis. Drug Des. Devel. Ther. 2010, 4:343-366.
4. Bartholomäus I., Kawakami N., Odoardi F., Schläger C., Miljkovic D., Ellwart J.W., Klinkert W.E., Flügel-Koch C., Issekutz T.B., Wekerle H., Flügel A. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
5. Bartholome B., Spies C.M., Gaber T., Schuchmann S., Berki T., Kunkel D., Bienert M., Radbruch A., Burmester G.R., Lauster R., Scheffold A., Buttgereit F. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. Faseb J. 2004, 18:70-80.
6. Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol. 2010, 120:69-75.
7. Baumann S., Dostert A., Novac N., Bauer A., Schmid W., Fas S.C., Krueger A., Heinzel T., Kirchhoff S., Schutz G., Krammer P.H. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood 2005, 106:617-625.
8. Becher B., Segal B.M. T(H)17 cytokines in autoimmune neuro-inflammation. Curr. Opin. Immunol. 2011, 23:707-712.
9. Billadeau D.D., Nolz J.C., Gomez T.S. Regulation of T-cell activation by the cytoskeleton. Nat. Rev. Immunol. 2007, 7:131-143.
10. Blecharz K.G., Haghikia A., Stasiolek M., Kruse N., Drenckhahn D., Gold R., Roewer N., Chan A., Förster C.Y. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult. Scler. 2010, 16:293-302.
11. Boldizsar F., Szabo M., Kvell K., Czompoly T., Talaber G., Bjorkan J., Bartis D., Nemeth P., Berki T. ZAP-70 tyrosines 315 and 492 transmit non-genomic glucocorticoid (GC) effects in T cells. Mol. Immunol. 2013, 53:111-117.
12. Bretscher A., Edwards K., Fehon R.G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 2002, 3:586-599.
13. Buck D., Hemmer B. Treatment of multiple sclerosis: current concepts and future perspectives. J. Neurol. 2011, 258:1747-1762.
14. Bunnell S.C., Kapoor V., Trible R.P., Zhang W., Samelson L.E. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity 2001, 14:315-329.
15. Cabarrocas J., Bauer J., Piaggio E., Liblau R., Lassmann H. Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 2003, 33:1174-1182.
16. Charcot J. Histologie de la sclérose en plaque. Gazette des HÔpitaux 1868, 41:554-566.
17. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
18. Coyle P.K. The role of natalizumab in the treatment of multiple sclerosis. Am. J. Manage. Care. 2010, 16:S164-S170.
19. Cronstein B.N., Kimmel S.C., Levin R.I., Martiniuk F., Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA 1992, 89:9991-9995.
20. Cruz-Orengo L., Holman D.W., Dorsey D., Zhou L., Zhang P., Wright M., McCandless E.E., Patel J.R., Luker G.D., Littman D.R., Russell J.H., Klein R.S. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J. Exp. Med. 2011, 208:327-339.
21. Delon J., Kaibuchi K., Germain R.N. Exclusion of CD43 from the immunological synapse is mediated by phosphorylation-regulated relocation of the cytoskeletal adaptor moesin. Immunity 2001, 15:691-701.
22. Dimitrov S., Benedict C., Heutling D., Westermann J., Born J., Lange T. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood 2009, 113:5134-5143.
23. DiSanto G., Morahan J.M., Barnett M.H., Giovannoni G., Ramagopalan S.V. The evidence for a role of B cells in multiple sclerosis. Neurology 2012, 78:823-832.
24. Elovaara I., Kuusisto H., Paalavuo R., Sarkijarvi S., Lehtimaki T., Huhtala H., Vilpo J. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta. Neurol. Scand. 2006, 113:163-166.
25. Elovaara I., Lalla M., Spare E., Lehtimaki T., Dastidar P. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 1998, 51:1703-1708.
26. Elovaara I., Ukkonen M., Leppakynnas M., Lehtimaki T., Luomala M., Peltola J., Dastidar P. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch. Neurol. 2000, 57:546-551.
27. Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J. Neurol. Sci. 2008, 274:23-26.
28. Engelhardt B., Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 2011, 8:4.
29. Engelhardt B., Ransohoff R.M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012, 33:579-589.
30. Faure S., Salazar-Fontana L.I., Semichon M., Tybulewicz V.L., Bismuth G., Trautmann A., Germain R.N., Delon J. ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat. Immunol. 2004, 5:272-279.
31. + T cell responses during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2005, 35:76-85.
32. + T cells in multiple sclerosis: a new target for therapy?. Brain 2005, 128:1747-1763.
33. Garvican E.R., Vaughan-Thomas A., Redmond C., Gabriel N., Clegg P.D. MMP-mediated collagen breakdown induced by activated protein C in equine cartilage is reduced by corticosteroids. J. Orthop. Res. 2010, 28:370-378.
34. Gautreau A., Louvard D., Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr. Opin. Cell Biol. 2002, 14:104-109.
35. Gelati M., Corsini E., De Rossi M., Masini L., Bernardi G., Massa G., Boiardi A., Salmaggi A. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch. Neurol. 2002, 59:774-780.
36. Ghosh M.C., Baatar D., Collins G., Carter A., Indig F., Biragyn A., Taub D.D. Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck. Blood 2009, 113:575-584.
37. Glass-Marmor L., Paperna T., Galboiz Y., Miller A. Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. J. Neuroimmunol. 2009, 210:124-127.
38. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
39. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285:221-227.
40. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F.P., Plumier J.C., Rebsamen M.C., Hsieh C.M., Chui D.S., Thomas K.L., Prorock A.J., Laubach V.E., Moskowitz M.A., French B.A., Ley K., Liao J.K. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 2002, 8:473-479.
41. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2004, 113:788-794.
42. Hench P. Effects of cortisone in the rheumatic diseases. Lancet 1950, 2:483-484.
43. Herold M.J., McPherson K.G., Reichardt H.M. Glucocorticoids in T cell apoptosis and function. Cell Mol. Life Sci. 2006, 63:60-72.
44. Holman D.W., Klein R.S., Ransohoff R.M. The blood-brain barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:220-230.
45. (+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
46. Izmailova E., Walker R., Fitzgerald M., Ocain T., Jaffee B., Healy A.M. Quantitation of peripheral blood markers of rat experimental autoimmune encephalomyelitis. Autoimmunity 2007, 40:355-365.
47. Jaerve A., Müller H.W. Chemokines in CNS injury and repair. Cell Tissue Res. 2012, 349:229-248.
48. Kabat E.A., Wolf A., Bezer A.E. The rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants. J. Exp. Med. 1947, 85:117-130.
49. Kiley S.C., Parker P.J., Fabbro D., Jaken S. Hormone- and phorbol ester-activated protein kinase C isozymes mediate a reorganization of the actin cytoskeleton associated with prolactin secretion in GH4C1 cells. Mol. Endocrinol. 1992, 6:120-131.
50. Kirsch S., Thijssen S., Alarcon Salvador S., Heine G.H., van Bentum K., Fliser D., Sester M., Sester U. T-cell numbers and antigen-specific T-cell function follow different circadian rhythms. J. Clin. Immunol. 2012, 32:1381-1389.
51. Kleiman A., Hübner S., Rodriguez Parkitna J.M., Neumann A., Hofer S., Weigand M.A., Bauer M., Schmid W., Schütz G., Libert C., Reichardt H.M., Tuckermann J.P. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. Faseb J. 2012, 26:722-729.
52. Klein R.S., Rubin J.B. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 2004, 25:306-314.
53. Koukouritaki S.B., Gravanis A., Stournaras C. Tyrosine phosphorylation of focal adhesion kinase and paxillin regulates the signaling mechanism of the rapid nongenomic action of dexamethasone on actin cytoskeleton. Mol. Med. 1999, 5:731-742.
54. Krummel M.F., Macara I. Maintenance and modulation of T cell polarity. Nat. Immunol. 2006, 7:1143-1149.
55. Krummel M.F., Sjaastad M.D., Wulfing C., Davis M.M. Differential clustering of CD4 and CD3 zeta during T cell recognition. Science 2000, 289:1349-1352.
56. Lee H.J., Choi S.C., Lee M.H., Oh H.M., Choi E.Y., Choi E.J., Yun K.J., Seo G.S., Kim S.W., Lee J.G., Han W.C., Park K.I., Jun C.D. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment. Inflamm. Bowel. Dis. 2005, 11:1070-1079.
57. Lee S.W., Tsou A.P., Chan H., Thomas J., Petrie K., Eugui E.M., Allison A.C. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc. Natl. Acad. Sci. USA 1988, 85:1204-1208.
58. Li M., Ransohoff R.M. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog. Neurobiol. 2008, 84:116-131.
59. Liu M., Hu X., Wang Y., Peng F., Yang Y., Chen X., Lu Z., Zheng X. Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse. Acta. Neurol. Scand. 2009, 120:235-241.
60. Lovett-Racke A.E., Yang Y., Racke M.K. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?. Biochim. Biophys. Acta. 2011, 1812:246-251.
61. Löwenberg M., Tuynman J., Bilderbeek J., Gaber T., Buttgereit F., van Deventer S., Peppelenbosch M., Hommes D. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 2005, 106:1703-1710.
62. Lu Y.C., Evans C.H., Grodzinsky A.J. Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines. Arthritis. Res. Ther. 2011, 13:R142.
63. Mahad D.J., Lawry J., Howell S.J., Woodroofe M.N. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult. Scler. 2003, 9:189-198.
64. Mandel I., Paperna T., Glass-Marmor L., Volkowich A., Badarny S., Schwartz I., Vardi P., Koren I., Miller A. Tight junction proteins expression and modulation in immune cells and multiple sclerosis. J. Cell Mol. Med. 2012, 16:765-775.
65. Mars L.T., Saikali P., Liblau R.S., Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim. Biophys. Acta. 2011, 1812:151-161.
66. McCandless E.E., Piccio L., Woerner B.M., Schmidt R.E., Rubin J.B., Cross A.H., Klein R.S. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 2008, 172:799-808.
67. McCandless E.E., Wang Q., Woerner B.M., Harper J.M., Klein R.S. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:8053-8064.
68. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
69. McFarlin D.E., McFarland H.F. Multiple sclerosis (first of two parts). N. Engl. J. Med. 1982, 307:1183-1188.
70. McFarlin D.E., McFarland H.F. Multiple sclerosis (second of two parts). N. Engl. J. Med. 1982, 307:1246-1251.
71. Medzhitov R., Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
72. Michalowska-Wender G., Losy J., Szczucinski A., Biernacka-Lukanty J., Wender M. Effect of methylprednisolone treatment on expression of sPECAM-1 and CXCL10 chemokine in serum of MS patients. Pharmacol. Rep. 2006, 58:920-923.
73. Michalowska-Wender G., Wender M. Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses. Folia Neuropathol. 2008, 46:134-138.
74. Milligan N.M., Newcombe R., Compston D.A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: one clinical effects. J. Neurol. Neurosurg. Psychiatry. 1987, 50:511-516.
75. Mirowska D., Wicha W., Czlonkowski A., Czlonkowska A., Weber F. Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J. Neuroimmunol. 2004, 146:171-175.
76. Mix E., Meyer-Rienecker H., Zettl U.K. Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J. Neurol. 2008, 255(Suppl 6):7-14.
77. Molon B., Gri G., Bettella M., Gomez-Mouton C., Lanzavecchia A., Martinez A.C., Manes S., Viola A. T cell costimulation by chemokine receptors. Nat. Immunol. 2005, 6:465-471.
78. Morita K., Sasaki H., Furuse M., Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J. Cell Biol. 1999, 147:185-194.
79. Mortier A., Van Damme J., Proost P. Overview of the mechanisms regulating chemokine activity and availability. Immunol. Lett. 2012, 145:2-9.
80. Moustakas A., Theodoropoulos P.A., Gravanis A., Haussinger D., Stournaras C. The cytoskeleton in cell volume regulation. Contrib. Nephrol. 1998, 123:121-134.
81. Moustaki A., Argyropoulos K.V., Baxevanis C.N., Papamichail M., Perez S.A. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function. Cancer Immunol. Immunother. 2011, 60:1683-1695.
82. Müller N., Fischer H.J., Tischner D., van den Brandt J., Reichardt H.M. Glucocorticoids induce effector T cell depolarization via ERM proteins, thereby impeding migration and APC conjugation. J Immunol. 2013, 190:4360-4370.
83. Nagase H., Miyamasu M., Yamaguchi M., Kawasaki H., Ohta K., Yamamoto K., Morita Y., Hirai K. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J. Allergy Clin. Immunol. 2000, 106:1132-1139.
84. Nguyen K.B., McCombe P.A., Pender M.P. Increased apoptosis of T lymphocytes and macrophages in the central and peripheral nervous systems of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. J. Neuropathol Exp. Neurol. 1997, 56:58-69.
85. Noseworthy J.H. Management of multiple sclerosis: current trials and future options. Curr. Opin. Neurol. 2003, 16:289-297.
86. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
87. Odoardi F., Sie C., Streyl K., Ulaganathan V.K., Schläger C., Lodygin D., Heckelsmiller K., Nietfeld W., Ellwart J., Klinkert W.E., Lottaz C., Nosov M., Brinkmann V., Spang R., Lehrach H., Vingron M., Wekerle H., Flügel-Koch C., Flügel A. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488:675-679.
88. Okutsu M., Ishii K., Niu K.J., Nagatomi R. Cortisol-induced CXCR4 augmentation mobilizes T lymphocytes after acute physical stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R591-R599.
89. Owens T., Tran E., Hassan-Zahraee M., Krakowski M. Immune cell entry to the CNS-a focus for immunoregulation of EAE. Res Immunol. 1998, 149:781-789. discussion 844-6, 855-60.
90. Pender M.P., Rist M.J. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 2001, 36:137-144.
91. Pitzalis C., Pipitone N., Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann. N. Y. Acad. Sci. 2002, 966:108-118.
92. Plotkin J., Prockop S.E., Lepique A., Petrie H.T. Critical role for CXCR4 signaling in progenitor localization and T cell differentiation in the postnatal thymus. J. Immunol. 2003, 171:4521-4527.
93. Reichardt H.M., Lühder F. The ambivalent role of apoptosis in experimental autoimmune encephalomyelitis and multiple sclerosis. Curr. Pharm. Des. 2012, 18:4453-4464.
94. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
95. Rivers T.M., Sprunt D.H., Berry G.P. Observations on attemps to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58.
96. Roumier A., Olivo-Marin J.C., Arpin M., Michel F., Martin M., Mangeat P., Acuto O., Dautry-Varsat A., Alcover A. The membrane-microfilament linker ezrin is involved in the formation of the immunological synapse and in T cell activation. Immunity 2001, 15:715-728.
97. Sallusto F., Impellizzieri D., Basso C., Laroni A., Uccelli A., Lanzavecchia A., Engelhardt B. T-cell trafficking in the central nervous system. Immunol. Rev. 2012, 248:216-227.
98. Sancho D., Vicente-Manzanares M., Mittelbrunn M., Montoya M.C., Gordon-Alonso M., Serrador J.M., Sanchez-Madrid F. Regulation of microtubule-organizing center orientation and actomyosin cytoskeleton rearrangement during immune interactions. Immunol Rev. 2002, 189:84-97.
99. Saxena A., Bauer J., Scheikl T., Zappulla J., Audebert M., Desbois S., Waisman A., Lassmann H., Liblau R.S., Mars L.T. Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J. Immunol. 2008, 181:1617-1621.
100. Schweingruber N., Reichardt S.D., Lühder F., Reichardt H.M. Mechanisms of glucocorticoids in the control of neuroinflammation. J. Neuroendocrinol. 2012, 24:174-182.
101. Shaffer M.H., Dupree R.S., Zhu P., Saotome I., Schmidt R.F., McClatchey A.I., Freedman B.D., Burkhardt J.K. Ezrin and moesin function together to promote T cell activation. J. Immunol. 2009, 182:1021-1032.
102. + T cell compartmentalization. Brain 2009, 132:1247-1258.
103. Slagsvold T., Marchese A., Brech A., Stenmark H. CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4. Embo J. 2006, 25:3738-3749.
104. Smith A., Carrasco Y.R., Stanley P., Kieffer N., Batista F.D., Hogg N. A talin-dependent LFA-1 focal zone is formed by rapidly migrating T lymphocytes. J. Cell Biol. 2005, 170:141-151.
105. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
106. Steiner O., Coisne C., Cecchelli R., Boscacci R., Deutsch U., Engelhardt B., Lyck R. Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. J. Immunol. 2010, 185:4846-4855.
107. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
108. + T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 2001, 166:7579-7587.
109. Tischner D., Theiss J., Karabinskaya A., van den Brandt J., Reichardt S.D., Karow U., Herold M.J., Lühder F., Utermöhlen O., Reichardt H.M. Acid sphingomyelinase is required for protection of effector memory T cells against glucocorticoid-induced cell death. J. Immunol. 2011, 187:4509-4516.
110. Tskvitaria-Fuller I., Rozelle A.L., Yin H.L., Wulfing C. Regulation of sustained actin dynamics by the TCR and costimulation as a mechanism of receptor localization. J. Immunol. 2003, 171:2287-2295.
111. Usher M.G., Duan S.Z., Ivaschenko C.Y., Frieler R.A., Berger S., Schütz G., Lumeng C.N., Mortensen R.M. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 2010, 120:3350-3364.
112. Valitutti S., Dessing M., Aktories K., Gallati H., Lanzavecchia A. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. 1995, 181:577-584.
113. van Loo G., Sze M., Bougarne N., Praet J., Mc Guire C., Ullrich A., Haegeman G., Prinz M., Beyaert R., De Bosscher K. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol. Endocrinol. 2010, 24:310-322.
114. Vicente-Manzanares M., Sanchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat. Rev. Immunol. 2004, 4:110-122.
115. Wang H.Y., Matsui M., Araya S., Onai N., Matsushima K., Saida T. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J. Neurol. Sci. 2003, 216:61-66.
116. Wekerle H., Schwab M., Linington C., Meyermann R. Antigen presentation in the peripheral nervous system: schwann cells present endogenous myelin autoantigens to lymphocytes. Eur. J. Immunol. 1986, 16:1551-1557.
117. Weller R.O., Engelhardt B., Phillips M.J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 1996, 6:275-288.
118. Wüst S., Tischner D., John M., Tuckermann J.P., Menzfeld C., Hanisch U.K., van den Brandt J., Lühder F., Reichardt H.M. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PloS one 2009, 4:e8202.
119. Wüst S., van den Brandt J., Tischner D., Kleiman A., Tuckermann J.P., Gold R., Lühder F., Reichardt H.M. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 2008, 180:8434-8443.
120. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990, 8:579-621.
121. Ziemssen T., Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun. Rev. 2005, 4:460-467.
122. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.